GNPS - Altered profiles of lipids and eicosanoids predict survival rate in patients with de novo or acute decompensated heart failure

Background: Heart failure (HF) is becoming an increasingly common problem, especially in the ageing population. Lipids are closely related to cardiovascular disease (CVD) pathology. Lipidomics as a comprehensive profiling tool is showing to be promising in the prediction of events and death due to CVD. In this study, eicosanoids and lipid profiles were measured to predict survival in patients with de novo or acute decompensated HF.
Methods: Our study involved 50 patients (16 females, aged 30-96 years, mean age 73 years and 34 males, aged 46-86 years, mean age 71 years) with de novo or acute decompensated chronic HF admitted to our tertiary cardiovascular centre with the median follow-up of 7 months. Lipids were semiquantified using targeted lipidomic LC-MS/MS analysis. The concentration of eicosanoids was determined by a commercially available sandwich ELISA assay.
Results: From 736 lipids and 3 eicosanoids we selected 39 significant lipids (by using the Mann-Whitney U test after Benjamini-Hochberg correction) where the highest number of representatives belonged to polyunsaturated phosphatidylcholines
(PC). PC 42:10 (p=1.44x10-4) was evaluated as the most statistically significant in the surviving group with receiver operating characteristics of AUC=0.84 (p=3.24x10-7).
Conclusion: Although the cardioprotective effect of polyunsaturated fatty acids (PUFA) is well known, in the present study we described a trend in PUFA esterified in PC, which were systematically elevated in surviving patients with HF. Using multivariate supervised discriminant analysis, the groups of surviving and non-surviving patients were classified with 90% accuracy.